VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Detail

ALVAC-HIV-2- env/gag/pol
Vaccine Information
  • Vaccine Name: ALVAC-HIV-2- env/gag/pol
  • Target Pathogen: Human Immunodeficiency Virus
  • Target Disease: Acquired Immunodeficiency Syndrome (AIDS)
  • Vaccine Ontology ID: VO_0004737
  • Type: Recombinant vector vaccine
  • Status: Research
  • Host Species for Licensed Use: Baboon
  • env gene engineering:
    • Type: Recombinant vector construction
    • Description: Live attenuated human immunodeficiency virus type 2 (HIV-2) vaccine alone versus boosting with live non-pathogenic HIV-2 following priming with ALVAC HIV-2 (recombinant canarypox virus expressing HIV-2 env, gag and pol) (Walther-Jallow et al., 2001).
    • Detailed Gene Information: Click Here.
  • gag gene engineering:
    • Type: Recombinant vector construction
    • Description: Live attenuated human immunodeficiency virus type 2 (HIV-2) vaccine alone versus boosting with live non-pathogenic HIV-2 following priming with ALVAC HIV-2 (recombinant canarypox virus expressing HIV-2 env, gag and pol) (Walther-Jallow et al., 2001).
    • Detailed Gene Information: Click Here.
  • Vector: ALVAC vaccine vector
  • Preparation: A live non-pathogenic HIV-2 following priming with ALVAC HIV-2 (recombinant canarypox virus expressing HIV-2 env, gag and pol) (Walther-Jallow et al., 2001).
  • Immunization Route: Intramuscular injection (i.m.)
Host Response

Monkey Response

  • Vaccination Protocol: Six monkeys were first inoculated intravenously with live HIV-2(SBL-6669) (Walther-Jallow et al., 2001).
  • Vaccine Immune Response Type: VO_0003057
  • Challenge Protocol: 7 to 10 months after vaccination, the monkeys were challenged intrarectally with 10 MID(50) of cell-free simian immunodeficiency virus (SIV) strain SIVsm (Walther-Jallow et al., 2001).
  • Efficacy: Vaccination with an ALVAC HIV-2 vaccine followed by exposure to live HIV-2 could induce cross-protection against mucosal infection with SIVsm and seemed to be more efficient than immunization with a live HIV-2 vaccine only (Walther-Jallow et al., 2001).
References
Walther-Jallow et al., 2001: Walther-Jallow L, Nilsson C, Söderlund J, ten Haaft P, Mäkitalo B, Biberfeld P, Böttiger P, Heeney J, Biberfeld G, Thorstensson R. Cross-protection against mucosal simian immunodeficiency virus (SIVsm) challenge in human immunodeficiency virus type 2-vaccinated cynomolgus monkeys. The Journal of general virology. 2001; 82(Pt 7); 1601-1612. [PubMed: 11413371].